Lefitolimod is under clinical development by Mologen and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Lefitolimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MGN-1703 (lefitolimod) is under development for the treatment of solid tumors, small cell lung cancer and chronic HIV-1 Infection. The drug candidate is administered subcutaneously as a solution. It acts by targeting Toll-like receptors 9 (TLR9). The drug candidate is based on dSLIM (double stem-loop immunomodulator) technology platform.
The drug candidate was under development for the treatment of metastatic colorectal carcer.
Mologen is a biotechnology engaged in the development of novel drugs, immunotherapies and active ingredients. The company develops various pipeline products which include MGN1601, and others. It also engaged in developing EnanDIM product to treat antitumor efficacy by stimulating TLR9 receptor on certain cells of the immune system. The company’s pipeline product Lefitolimod acts like a toll receptor which helps in activating the immune system. It also develops tolerable drugs in fields of oncology and on other serious infectious diseases. Mologen is headquartered in Berlin, Germany.
For a complete picture of Lefitolimod’s drug-specific PTSR and LoA scores, buy the report here.